US court continues to prevent Teva from shipping any additional
generic copies of the high blood pressure medicine Lotrel
* US court extends temporary restraining order blocking new Lotrel
generics deliveries but continues to allow sale of generics
already shipped to customers
* Order extended until court ruling on an earlier preliminary
injunction to block Teva from selling generic copies of Lotrel
Basel, May 29, 2007 - A US federal court judge has extended a
temporary restraining order stopping Teva Pharmaceutical Industries
Ltd. from shipping any further supplies of a generic version of the
high blood pressure medicine Lotrel®.
However, the judge also continued to allow the sale of generic copies
of Lotrel that had reached distributors and customers before the
initial temporary restraining order on May 19.
This order has been extended until a ruling from a judge in the US
District Court for the District of New Jersey on an earlier request
from Novartis for a preliminary injunction to stop Teva from selling
its generic version of Lotrel. This ruling is expected in the near
future.
Disclaimer
The foregoing release contains forward-looking statements which can
be identified by the use of terminology such as "expected", "will
continue", or similar expressions, or by express or implied
discussions regarding the patent life of Lotrel, the potential for
the continued maintenance of the injunction imposed against Teva, the
potential for Novartis to succeed in the underlying litigation
against Teva, potential future revenue to be earned from Lotrel and
the potential impact of Teva's actions on the net sales, operating
income and net income results for Novartis. Such forward-looking
statements involve known and unknown risks, uncertainties and other
factors that may cause actual results to be materially different from
any future results, performance or achievements expressed or implied
by such statements. There can be no guarantee that Novartis will be
successful in its efforts to defend its Lotrel patent, or that the
court will continue to impose an injunction against the marketing of
a generic version of Lotrel by Teva, or that Novartis will ultimately
succeed in its litigation against Teva. Neither can there be any
guarantees that Lotrel will achieve or maintain any particular sales
levels in the future or that the Novartis Group will achieve any
particular levels of net sales, operating income or net income
results. In particular, management's expectations regarding Lotrel
could be affected by, among other things, uncertainties involved in
US patent law and the US litigation process; the company's ability to
maintain patent or other proprietary intellectual property
protection; increased government, industry, and general public
pricing pressures; competition in general; unexpected regulatory
actions or delays or government regulation generally; and other risks
and factors referred to in Novartis AG's current Form 20-F on file
with the US Securities and Exchange Commission. Should one or more of
these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results may vary materially from
those anticipated, believed, estimated or expected. Novartis is
providing the information in this press release as of this date and
does not undertake any obligation to update any forward-looking
statements contained in this press release as a result of new
information, future events or otherwise.
About Novartis
Novartis AG (NYSE: NVS) is a world leader in offering medicines to
protect health, cure disease and improve well-being. Our goal is to
discover, develop and successfully market innovative products to
treat patients, ease suffering and enhance the quality of life. We
are strengthening our medicine-based portfolio, which is focused on
strategic growth platforms in innovation-driven pharmaceuticals,
high-quality and low-cost generics, human vaccines and leading
self-medication OTC brands. Novartis is the only company with
leadership positions in these areas. In 2006, the Group's businesses
achieved net sales of USD 37.0 billion and net income of USD 7.2
billion. Approximately USD 5.4 billion was invested in R&D.
Headquartered in Basel, Switzerland, Novartis Group companies employ
approximately 100,000 associates and operate in over 140 countries
around the world. For more information, please visit
http://www.novartis.com.
# # #
Novartis Media Relations
John Gilardi Sherry Pudloski
Novartis Global Media Relations Novartis Pharmaceuticals
Corporation
+41 61 324 3018 (direct) +1 862 778 1271 (direct)
+41 79 596 1408 (mobile) +1 917 620 4446 (mobile)
john.gilardi@novartis.com sherry.pudloski@novartis.com
e-mail: media.relations@novartis.com
Novartis Investor Relations
International:
Ruth Metzler-Arnold +41 61 324 7944
Katharina Ambühl +41 61 324 5316
Nafida Bendali +41 61 324 3514
Jason Hannon +41 61 324 2152
Thomas Hungerbuehler +41 61 324 8425
Richard Jarvis +41 61 324 4353
North America:
Ronen Tamir +1 212 830 2433
Arun Nadiga +1 212 830 2444
Jill Pozarek +1 212 830 2445
Edwin Valeriano +1 212 830 2456
e-mail: investor.relations@novartis.com
--- End of Message ---
Novartis International AG
Posfach Basel
WKN: 904278; ISIN:
CH0012005267; Index: SLCI, SMI, SPI, SLIFE;
Listed: Main Market in SWX Swiss Exchange, ZLS in BX Berne eXchange;